Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells

Cancer Letters

Volumn 272, Issue 1, 2008, Pages 53-60

  Łuczak, Michał W ^a   Jagodzinski, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Apicidin; Cervical cancer cells; Histone deacetylase; Signaling molecules

Indexed keywords

APICIDIN; CYCLOHEXIMIDE; DACTINOMYCIN; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBONUCLEASE;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA STABILITY; UTERINE CERVIX CANCER; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HISTONE DEACETYLASES; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PEPTIDES, CYCLIC; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 53949094562     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.06.030     Document Type: Article

References (57)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Campisi G., Panzarella V., Giuliani M., Lajolo C., Di Fede O., Falaschini S., Di Liberto C., Scully C., and Lo Muzio L. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. Int. J. Oncol. 30 (2007) 813-823
3. Baker C.C., Phelps W.C., Lindgren V., Braun M.J., Gonda M.A., and Howley P.M. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61 (1987) 962-971
4. McBride A.A., Romanczuk H., and Howley P.M. The papillomavirus E2 regulatory proteins. J. Biol. Chem. 266 (1991) 18411-18414
5. Chiang C.M., Ustav M., Stenlund A., Ho T.F., Broker T.R., and Chow L.T. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins. Proc. Natl. Acad. Sci. USA 89 (1992) 5799-5803
6. DiMaio D., and Mattoon D. Mechanisms of cell transformation by papillomavirus E5 proteins. Oncogene 54 (2001) 7866-7873
7. Tsai T.C., and Chen S.L. The biochemical and biological functions of human papillomavirus type 16 E5 protein. Arch. Virol. 148 (2003) 1445-1453
8. Kivi N., Greco D., Auvinen P., and Auvinen E. Genes involved in cell adhesion cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expression. Oncogene 27 (2008) 2532-2541
9. zur Hausen H. Papillomaviruses in human cancers. Proc. Assoc. Am. Phys 111 6 (1999) 581-587
10. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
11. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 32 (2005) S1-S6
12. Molijn A., Kleter B., Quint W., and van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 32 (2005) S43-S51
13. Bernard H.U., Calleja-Macias I.E., and Dunn S.T. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer 118 (2006) 1071-1076
14. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., and Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 1-3
15. van der Graaf Y., Molijn A., Doornewaard H., Quint W., van Doorn L.J., and van den Tweel J. Human papillomavirus and the long-term risk of cervical neoplasia. Am. J. Epidemiol. 156 (2002) 158-164
16. Dueñas-González A., Lizano M., Candelaria M., Cetina L., Arce C., and Cervera E. Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol. Cancer 25 (2005) 4-38
17. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., and Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8 (1989) 3905-3910
18. Münger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res. 89 (2002) 213-228
19. Riley R.R., Duensing S., Brake T., Münger K., Lambert P.F., and Arbeit J.M. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 63 (2003) 4862-4871
20. Huibregtse J.M., Scheffner M., and Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding association with p53 and ubiquitination of associated proteins. Mol. Cell. Biol. 13 (1993) 4918-4927
21. Scheffner M., Huibregtse J.M., Vierstra R.D., and Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75 (1993) 495-505
22. Klingelhutz A.J., Foster S.A., and McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 280 (1996) 79-82
23. Sprague D.L., Phillips S.L., Mitchell C.J., Berger K.L., Lace M., Turek L.P., and Klingelhutz A.J. Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes. Virology 301 (2002) 247-254
24. Huh K.W., DeMasi J., Ogawa H., Nakatani Y., Howley P.M., and Münger K. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc. Natl. Acad. Sci. USA 102 (2005) 11492-11497
25. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., Harper J.W., and Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J. Virol. 81 (2007) 9737-9747
26. Richardson B., and Yung R. Role of DNA methylation in the regulation of cell function. J. Lab. Clin. Med. 134 (1999) 333-340
27. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., and Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983 983 (2003) 84-100
28. Luczak M.W., and Jagodzinski P.P. The role of DNA methylation in cancer development. Folia Histochem. Cytobiol. 44 (2006) 143-154
29. Kalantari M., Calleja-Macias I.E., Tewari D., Hagmar B., Lie K., Barrera-Saldana H.A., Wiley D.J., and Bernard H.U. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J. Virol. 78 (2004) 12762-12772
30. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., Kwon H.K., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60 (2000) 6068-6074
31. Kim S., Kang J.K., Kim Y.K., Seo D.W., Ahn S.H., Lee J.C., Lee C.H., You J.S., Cho E.J., Lee H.W., and Han J.W. Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem. Biophys. Res. Commun. 342 (2006) 1168-1173
32. Kim Y.K., Seo D.W., Kang D.W., Lee H.Y., Han J.W., and Kim S.N. Involvement of HDAC1 and the PI3K/PKC signaling pathways in NF-κB activation by the HDAC inhibitor apicidin. Biochem. Biophys. Res. Commun. 347 (2006) 1088-1093
33. Januchowski R., Dabrowski M., Ofori H., and Jagodzinski P.P. Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells. Cancer Lett. 246 (2007) 313-317
34. Januchowski R., and Jagodzinski P.P. Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells. Int. Immunopharmacol. 7 (2007) 198-204
35. + T cell responses. BMC Cancer 3 (2003) 30
36. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
37. Radonić A., Thulke S., Mackay I.M., Landt O., Siegert W., and Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. 313 (2004) 856-862
38. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., and van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370 (2003) 737-749
39. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528
40. Acharya M.R., Sparreboom A., Venitz J., and Figg W.D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 68 (2005) 917-932
41. Darkin-Rattray S.J., Gurnett A.M., Myers R.W., Dulski P.M., Crumley T.M., Allocco J.J., Cannova C., Meinke P.T., Colletti S.L., Bednarek M.A., Singh S.B., Goetz M.A., Dombrowski A.W., Polishook J.D., and Schmatz D.M. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA 93 (1996) 13143-13147
42. Singh S.B., Zink D.L., Liesch J.M., Dombrowski A.W., Darkin-Rattray S.J., Schmatz D.M., and Goetz M.A. Structure, histone deacetylase, and antiprotozoal activities of apicidins B and C, congeners of apicidin with proline and valine substitutions. Org. Lett. 3 (2001) 2815-2818
43. Singh S.B., Zink D.L., Liesch J.M., Mosley R.T., Dombrowski A.W., Bills G.F., Darkin-Rattray S.J., Schmatz D.M., and Goetz M.A. Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal α-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities. J. Org. Chem. 67 (2002) 815-825
44. García-Vallvé S., Iglesias-Rozas J.R., Alonso A., and Bravo I.G. Different papillomaviruses have different repertoires of transcription factor binding sites: convergence and divergence in the upstream regulatory region. BMC Evol. Biol. (2006) 6:20
45. Tang S., Tao M., McCoy Jr J.P., and Zheng Z.M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 80 (2006) 4249-4263
46. Sathish N., Abraham P., Peedicayil A., Sridharan G., John S., and Chandy G. Human papillomavirus 16 E6/E7 transcript and E2 gene status in patients with cervical neoplasia. Mol. Diagn. 8 (2004) 57-64
47. Han J.W., Ahn S.H., Kim Y.K., Bae G.U., Yoon J.W., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Activation of p21 (WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J. Biol. Chem. 276 (2001) 42084-42090
48. Kim Y.K., Han J.W., Woo Y.N., Chun J.K., Yoo J.Y., J Cho E., Hong S., Lee H.Y., Lee Y.W., and Lee H.W. Expression of p21 (WAF1/Cip1) through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase-PKC epsilon signaling pathway. Oncogene 22 (2003) 6023-6031
49. Cheong J.W., Chong S.Y., Kim J.Y., Eom J.I., Jeung H.K., Maeng H.Y., Lee S.T., and Min Y.H. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin. Cancer Res. 9 (2003) 5018-5027
50. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., Kim M.R., Kim K.W., Kim W.B., and Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun. 315 (2004) 964-970
51. Kim S.H., Jeong J.W., Park J.A., Lee J.W., Seo J.H., Jung B.K., Bae M.K., and Kim K.W. Regulation of the HIF-1α stability by histone deacetylases. Oncol. Rep. 17 (2007) 647-651
52. You J.S., Kang J.K., Lee E.K., Lee J.C., Lee S.H., Jeon Y.J., Koh D.H., Ahn S.H., Seo D.W., Lee H.Y., Cho E.J., and Han J.W. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene (2007) 10.1038/sj.onc.1210776
53. Xiong Y., Dowdy S.C., Podratz K.C., Jin F., Attewell J.R., Eberhardt N.L., and Jiang S.W. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 65 (2005) 2684-2689
54. Takaki T., Fukasawa K., Suzuki-Takahashi I., and Hirai H. Cdk-mediated phosphorylation of pRB regulates HDAC binding in vitro. Biochem. Biophys. Res. Commun. 316 (2004) 252-255
55. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., and Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 6667 (1998) 597-601
56. Martínez-Balbás M.A., Bauer U.M., Nielsen S.J., Brehm A., and Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J. 19 (2000) 662-671
57. Marzio G., Wagener C., Gutierrez M.I., Cartwright P., Helin K., and Giacca M. E2F family members are differentially regulated by reversible acetylation. J. Biol. Chem. 275 (2000) 10887-10892